Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Sirona Biochem Corp
Bullboard Posts
User Avatar Image
(1)
•••
Post by Geheimnisvolleron Oct 01, 2019 2:48pm
554 Views
Post# 30183369

Small-cap-investor interview from Swiss Brunner

Small-cap-investor interview from Swiss BrunnerSmall-cap-investor interview from Swiss Brunner

https://www.youtube.com/watch?v=xmO21SAUWsY&feature=youtu.be

The followings are very interesting

- this and next year financials are OK
- FDA for skinlightner not necessary
- Rodan and Fields are making lot of work to launch their product
- Publication is on the way and will show the world the skinlightner
- Sirona seeks big production, even they need only low concentrations - that means lot of deals
- Asia markets much bigger than R&F
- Sirona is making realy great progress there, never busier than now
- Wanbang very advanced levels how we can work more together
- antiwrinkle is a very big thing !!!!!!!!!!!!!!
- soon great news from Wangling
- animal is a very interesting market as well
- we anticipate news to follow
- Sirona is sorting out how to make expanding capacity - this means lots and big deals in the future
- Howard: we are doing very well, we have the financials to do all these projects
- News concerning Skinlightner, Wangbang, anti-aging, animals in the next six months, Howard: we hope sooner !!!!!!!!!!!!!! 

Sirona Biochem | wallstreet-online.de - Vollstndige Diskussion unter:
https://www.wallstreet-online.de/diskussion/1183167-16691-16700/sirona-biochem
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities